8-K: MaxCyte Reports Mixed 2023 Results, Reaffirms 2024 Guidance

MaxCyte's fourth quarter saw a revenue increase driven by its Strategic Platform License program, while full-year results showed a decline in core business revenue.

Summary

• MaxCyte announced its financial results for the fourth quarter and full year ended December 31, 2023.
• Total revenue for the fourth quarter of 2023 was $15.7 million, a 26% increase compared to the same period in 2022.
• However, core business revenue for the fourth quarter decreased by 32% to $7.2 million.
• Strategic Platform License (SPL) program revenue surged by 359% to $8.5 million in the fourth quarter.
• For the full year 2023, total revenue was $41.3 million, a 7% decrease compared to 2022.
• Core business revenue for the full year declined by 25% to $29.8 million.
• SPL program revenue for the full year increased by 148% to $11.5 million.
• The company ended the year with 23 active SPL agreements, covering over 160 potential programs.
• MaxCyte had $211.2 million in cash, cash equivalents, and investments as of December 31, 2023.
• The company is reiterating its 2024 revenue guidance, expecting flat to 5% growth in core business revenue and approximately $3 million in SPL program-related revenue, excluding a significant milestone from 2023.

Sentiment

Score: 5

Explanation: The sentiment is neutral to slightly negative due to the mixed results. While the SPL program is performing well, the decline in core business revenue and increased losses are concerning. The reiteration of 2024 guidance provides some stability, but the overall picture is not overwhelmingly positive.

Positives

• Fourth quarter total revenue increased by 26% year-over-year, driven by strong growth in SPL program revenue.
• SPL program revenue increased significantly, both in the fourth quarter (359%) and for the full year (148%).
• The company has a growing number of active SPL agreements, indicating strong future potential.
• MaxCyte maintains a high gross profit margin, at 90% for the fourth quarter and 89% for the full year.
• The company has a strong cash position of $211.2 million as of December 31, 2023.
• The company has reiterated its 2024 revenue guidance.

Negatives

• Core business revenue declined by 32% in the fourth quarter and 25% for the full year.
• Cell therapy revenue decreased by 27% in the fourth quarter and 25% for the full year.
• Drug discovery revenue decreased by 46% in the fourth quarter and 23% for the full year.
• The company experienced a net loss of $5.3 million in the fourth quarter and $37.9 million for the full year.
• Operating expenses increased to $22.2 million in the fourth quarter and $84.8 million for the full year.
• EBITDA was a loss of $7.0 million for the fourth quarter and $44.1 million for the full year.

Risks

• The company is facing a challenging operating environment with increased capital conservatism and pipeline portfolio reevaluation among its customers.
• The decline in core business revenue and cell therapy revenue could impact future growth.
• The company's operating expenses are increasing, which could affect profitability.
• The company's future performance is dependent on the success of its SPL program and the ability of its partners to commercialize their products.
• The company's 2024 guidance does not include SPL Program-related revenue from Vertex/CRISPRs CASGEVYTM, which could impact revenue.

Future Outlook

Management expects full year 2024 core business revenue to be flat to 5% growth compared to 2023, and SPL Program-related revenue is expected to be approximately $3 million. The company expects to end 2024 with $175 million in total cash, cash equivalents and investments.

Management Comments

• Maher Masoud, President and CEO of MaxCyte, stated that the team adapted well to the changing environment in 2023 and he is confident in their ability to execute across the business in 2024.
• Management is pleased with the accomplishments and progress in 2023, including supporting the FDA approval of CASGEVYTM by Vertex Pharmaceuticals.
• The company's pipeline of potential clients remains robust, and they look forward to further expanding their portfolio of SPLs in 2024.

Industry Context

The announcement reflects the challenges faced by companies in the cell therapy industry, including increased capital conservatism and pipeline portfolio reevaluation among customers. MaxCyte's focus on its SPL program aligns with the industry's growing interest in platform technologies for cell therapy development.

Comparison to Industry Standards

• MaxCyte's 89-90% gross margin is very high compared to many other biotech companies, indicating a strong pricing power or cost structure.
• The company's reliance on SPL revenue is similar to other platform technology companies in the biotech space, such as those providing gene editing or drug delivery technologies.
• The decline in core business revenue is a concern, as it suggests a potential weakness in the company's traditional business model, which is in contrast to the growth seen in the SPL program.
• The company's cash position of $211.2 million is relatively strong, providing a buffer for future operations and investments, but the cash burn rate is a concern.
• The company's EBITDA loss of $44.1 million for the year is significant and needs to be addressed to achieve profitability.

Stakeholder Impact

• Shareholders may be concerned about the decline in core business revenue and the increased net loss.
• Employees may be affected by the company's performance and future strategic decisions.
• Customers may be impacted by the company's focus on SPL programs and potential changes in its core business offerings.
• Suppliers may be affected by changes in the company's purchasing patterns.
• Creditors may be concerned about the company's financial performance and ability to repay debts.

Next Steps

• MaxCyte will focus on executing its 2024 plan, aiming to be the industry's premier non-viral cell therapy platform.
• The company will continue to expand its portfolio of SPLs in 2024.
• MaxCyte will host a conference call on March 12, 2024, to discuss the financial results.

Key Dates

Keywords

MaxCyte, cell therapy, strategic platform license, SPL, revenue, financial results, bioprocessing, electroporation, EBITDA, core business, guidance